Supporting the biochemical diagnosis of mucopolysaccharidoses types IIIA, IIIB, IIIC, IIID
This test is not useful for carrier detection.
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Acetyl-CoA:glucosamine acetyltransferase
GNS
Heparan-alpha-glucosaminide N-acetyltransferase
Heparan-N-sulfatase
Heparan sulfate sulfatase
HGSNAT
MPS IIIA
MPS IIIB
MPS IIIC
MPS IIID
Mucopolysaccharidosis
N-acetyl-alpha-D-glucosaminidase
N-acetyl glucosamine-6-sulfatase
N-acetylglucosaminidase
NAGLU
SGSH
Whole Blood ACD
For optimal isolation of leukocytes, it is recommended the specimen arrive refrigerated within 6 days of collection to be stabilized. Collect specimen Monday through Thursday only and not the day before a holiday. Specimen should be collected and packaged as close to shipping time as possible.
1. Patient's age is required.
2. Reason for testing is required.
Question ID | Description | Answers |
---|---|---|
BG767 | Reason for Referral |
Rule out MPS III Follow up of known MPS IIIA Follow up of known MPS IIIB Follow up of known MPS IIIC Follow up of known MPS IIID Not Provided |
Container/Tube:
Preferred: Yellow top (ACD solution B)
Acceptable: Yellow top (ACD solution A) or lavender top (EDTA)
Specimen Volume: 6 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Biochemical Genetics Patient Information (T602)
3. If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.
5 mL
Gross hemolysis | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole Blood ACD | Refrigerated (preferred) | 6 days | |
Ambient | 6 days |
Supporting the biochemical diagnosis of mucopolysaccharidoses types IIIA, IIIB, IIIC, IIID
This test is not useful for carrier detection.
Mucopolysaccharidosis III (MPS III; Sanfilippo syndrome) is caused by reduced or absent activity of 1 of 4 enzymes involved in heparan sulfate degradation. Patients with MPS III uniformly excrete heparan sulfate resulting in similar clinical phenotypes and are further classified as type A, B, C, or D based upon the specific enzyme deficiency. MPS III is characterized by severe central nervous system (CNS) degeneration but only mild physical disease. Such disproportionate involvement of the CNS is unique among the MPS. Onset of clinical features, most commonly behavioral problems and delayed development, usually occurs between 2 and 6 years of age in a child who previously appeared normal. Severe neurologic degeneration occurs in most patients by 6 to 10 years of age accompanied by a rapid deterioration of social and adaptive skills with death generally occurring by their 20s. The occurrence of MPS III varies by subtype with types A and B being the most common and types C and D being very rare. The collective incidence is approximately 1 in 58,000 live births. This assay detects all MPSIII types (MPS IIIA, IIIB, IIIC, and IIID).
A diagnostic workup for MPS typically also includes GAG determination in urine (MPSQU / Mucopolysaccharides Quantitative, Random, Urine) or blood (MPSBS / Mucopolysaccharidosis, Blood Spot, or MPSER / Mucopolysaccharides Quantitative, Serum) and molecular genetic analysis of the relevant gene(s). For MPS III, a molecular panel is available that includes SGSH, NAGLU, GNS, HGSNAT (CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies; specify Gene List ID: IEMCP-7YM613).
HEPARAN-N-SULFATASE:
>0.13 nmol/hour/mg protein
N-ACETYL-ALPHA-D-GLUCOSAMINIDASE:
>0.09 nmol/hour/mg protein
HEPARAN-ALPHA-GLUCOSAMINIDE N-ACETYLTRANSFERASE:
>0.24 nmol/hour/mg protein
N-ACETYLGLUCOSAMINE-6-SULFATASE:
>0.03 nmol/hour/mg protein
An interpretive report will be provided.
Abnormal results are not sufficient to establish a diagnosis of a particular disease. To verify a preliminary diagnosis based on this assay, additional biochemical or molecular genetic analyses are required.
When abnormal results are detected, a detailed interpretation is given, including an overview of the results and of their significance, a correlation to available clinical information, elements of differential diagnosis, recommendations for additional biochemical testing and in vitro confirmatory studies (enzyme assay, molecular analysis), and a phone number to reach one of the laboratory directors in case the referring physician has additional questions.
Individuals with pseudodeficiency alleles can show reduced enzyme activity.
Carrier status (heterozygosity) for these conditions cannot be reliably detected.
Enzyme levels may be normal in individuals receiving enzyme replacement therapy or who have undergone hematopoietic stem cell transplant.
1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA. eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; Accessed July 18, 2023. https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225544161
2. Hopwood JJ, Ballabio A. Multiple sulfatase deficiency and the nature of the sulfatase family. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA. eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; Accessed July 18, 2023. https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225546905
Leukocytes are incubated with four cocktail mixes: 1) substrate and internal standard (IS) for iduronate 2-sulfatase, heparan N-sulfatase, alpha-N-acetylglucosaminidase, N-acetylgalactosamine-sulfate, beta-galactosidase, arylsulfatase B, beta-glucuronidase, and tripeptidyl peptidase 1; 2) substrate and IS for acetyl-CoA:alpha-glucosaminide N-acetyltransferase; 3) substrate and IS for N-acetylglucosamine-6-sulfatase; and 4) substrate and IS for palmitoyl-protein thioesterase 1 in 96-well plates. Following overnight incubation, the plates are combined and purified by liquid-liquid extraction. The extracts are evaporated, reconstituted with mobile phase, and analyzed by tandem mass spectrometry.(Unpublished Mayo method)
Preanalytical processing: Monday through Saturday
Testing performed: Tuesday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
82657
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
MPS3W | MPS III (Four) Panel, WBC | 104072-4 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
BG767 | Reason for Referral | 42349-1 |
618456 | Heparan-N-sulfatase | 24086-1 |
618457 | N-acetyl-alpha-D-glucosaminidase | 24092-9 |
618458 | Heparan-alpha-glucosaminide N-acetyltransferase | 24044-0 |
618459 | N-acetylglucosamine-6-sulfatase | 24098-6 |
618460 | Interpretation | 59462-2 |
618455 | Reviewed By | 18771-6 |
Change Type | Effective Date |
---|---|
New Test | 2023-10-17 |